[1]许向波,周新苗,郭晓钟,等.非选择性β受体阻滞剂在终末期肝病中的应用现状[J].医学信息,2018,31(09):23-25.[doi:10.3969/j.issn.1006-1959.2018.09.007]
　XU Xiang-bo,ZHOU Xin-miao,GUO Xiao-zhong,et al.The Application Status of Non-selective β-blocker in End-stage Liver Disease[J].Journal of Medical Information,2018,31(09):23-25.[doi:10.3969/j.issn.1006-1959.2018.09.007]
点击复制

非选择性β受体阻滞剂在终末期肝病中的应用现状()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年09期
页码:
23-25
栏目:
出版日期:
2018-05-01

文章信息/Info

Title:
The Application Status of Non-selective β-blocker in End-stage Liver Disease
文章编号:
1006-1959（2018）09-0023-03
作者:
许向波1; 2; 周新苗2; 郭晓钟2; 祁兴顺2
1.沈阳药科大学研究生院，辽宁 沈阳 110016； 2.沈阳军区总院消化内科，辽宁 沈阳 110840
Author(s):
XU Xiang-bo1; 2; ZHOU Xin-miao2; GUO Xiao-zhong2; QI Xing-shun2
1.Graduate School of Shenyang Pharmaceutical University,Shenyang 110016,Liaoning,China; 2.Department of Gastroenterology,Shenyang Military Region General Hospital,Shenyang 110840,Liaoning,China
关键词:
非选择性β受体阻滞剂; 食管静脉曲张; 食管静脉曲张出血
Keywords:
Key words：Non-selective β-blocker; Esophageal varices; Esophageal variceal bleeding
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2018.09.007
文献标志码:
A
摘要:
食管静脉曲张出血是门脉高压的并发症之一。非选择性β受体阻滞剂可通过拮抗β1受体和β2受体降低门脉高压，用于食管静脉曲张出血的一级预防和二级预防。本文旨在评述非选择性β受体阻滞剂在终末期肝病患者中的应用现状。
Abstract:
Abstract：Esophageal variceal bleeding is one of the complications of portal hypertension.Non-selective β-blockers can reduce portal hypertension by antagonizing β1 and β2 receptors for primary and secondary prevention of esophageal variceal bleeding.This article aims to review the current status of non-selective β-blockers in patients with end-stage liver disease.

参考文献/References:

[1]Kovalak M,Lake J,Mattek N,et al.Endoscopic screening for varices in cirrhotic patients:data from a national endoscopic database[J].Gastrointestinal Endoscopy,2007,65(1):82-88.
[2]韩丹,祁兴顺,于洋,等.《2016年美国肝病学会肝硬化门静脉高压出血的风险分层、诊断和管理实践指导》摘译[J].临床肝胆病杂志,2017,33(3):422-427.
[3]杨春娇,祁兴顺,郭晓钟.卡维地洛治疗肝硬化门静脉高压的研究进展[J].临床肝胆病杂志,2015,31(3):469-471.
[4]Bai M,Qi X,Yang M,et al.Combined therapies versus monotherapies for the first variceal bleeding in patients with high-risk varices:a meta-analysis of randomized controlled trials[J].Journal of Gastroenterology&Hepatology,2014,29(3):442-452.
[5]Tripathi D,Graham C,Hayes PC.Variceal band ligation versus beta-blockers for primary prevention of variceal bleeding:a meta-analysis[J].European Journal of Gastroenterology&Hepatology,2007,19(10):835-845.
[6]Gluud LL,Krag A.Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J].Cochrane Database of Systematic Reviews,2012,8(8):CD004544.
[7]Thiele M,Krag A,Rohde U,et al.Meta-analysis:banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices[J].Alimentary Pharmacology&Therapeutics,2012,35(10):1155-1165.
[8]Puente A,Hernandez-Gea V,Graupera I,et al.Drugs plus ligation to prevent rebleeding in cirrhosis:an updated systematic review[J].Liver International,2014,34(6):823-833.
[9]Qi X,Mendez-Sanchez N,Mancuso A,et al.Who should receive endoscopic variceal ligation after recovering from acute variceal bleeding[J].Hepatology,2018,67(5):2057-2058.
[10]Angeli P,Bernardi M,Villanueva C,et al.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J].Journal of Hepatology,2018(18):31966-31964.
[11]彭颖,祁兴顺,郭晓钟,等.2015年Baveno Ⅵ共识:门静脉高压的风险分层及个体化管理[J].临床肝胆病杂志,2015,31(08):1202-1207.
[12]邓晗,祁兴顺,郭晓钟.《2015年英国肝硬化静脉曲张出血防治指南》摘译[J].临床肝胆病杂志,2015,31(6):852-854.
[13]徐小元,丁惠国,贾继东,等.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志,2016,32(02):203-219.
[14]Qi XS,Bao YX,Bai M,et al.Nonselective beta-blockers in cirrhotic patients with no or small varices:A meta-analysis[J].World Journal of Gastroenterology,2015,21(10):3100-3108.
[15]Kumar A,Sharma P,Anikhindi SA,et al.Can Non-Selective Beta-Blockers(NSBBs)Prevent Enlargement of Small Esophageal Varices in Patients with Cirrhosis a Meta-analysis[J].Journal of Clinical and Experimental Hepatology,2017,7(4):275-283.
[16]Serste T,Melot C,Francoz C,et al.Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J].Hepatology,2010,52(3):1017-1022.
[17]Leithead JA,Rajoriya N,Tehami N,et al.Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation[J].Gut,2015,64(7):1111-1119.
[18]Bossen L,Krag A,Vilstrup H,et al.Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites:Post Hoc analysis of three randomized controlled trials with 1198 patients[J].Hepatology,2016,63(6):1968-1976.
[19]Chirapongsathorn S,Valentin N,Alahdab F,et al.Nonselective beta-Blockers and Survival in Patients With Cirrhosis and Ascites:A Systematic Review and Meta-analysis[J].Clinical Gastroenterology&Hepatology,2016,14(8):1096-1104.
[20]Qi XS,Bai M,Fan DM.Nonselective beta-blockers may induce development of portal vein thrombosis in cirrhosis[J].World Journal of Gastroenterology,2014,20(32):11463-11466.
[21]Zampino R,Lebano R,Coppola N,et al.The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients[J].Saudi Journal of Gastroenterology,2018,24(1):25-29.
[22]Violi F,Corazza GR,Caldwell SH,et al.Portal vein thrombosis relevance on liver cirrhosis:Italian Venous Thrombotic Events Registry[J].Internal and Emergency Medicine,2016,11(8):1059-1066.

更新日期/Last Update: 2018-05-01